UPDATED: Celgene pays $1B in landmark deal to buy into Juno’s pipeline of CAR-T drugs

John Carroll Celgene is paying about $ 1 billion to move to the front of the hectic race to build new CAR-T cancer therapies. The Big Biotech is shelling out $ 150 million upfront ...

Sanofi buys into NeuroVive’s cardio drug in Korea

Damian Garde Sanofi is betting on the promise of NeuroVive Pharmaceutical's top prospect, buying the South Korean rights to the biotech's Phase III cardiovascular drug. FierceBiotech ...

Bellicum buys into CAR-T manufacturing amid a hot immuno-oncology race

Damian Garde Following the lead of Juno Therapeutics and Kite Pharma, CAR-T contender Bellicum Pharmaceuticals is splashing cash on an in-house manufacturing operation, speeding its ...

Gilead jumps into epigenetics with a bite-size biotech buyout

Damian Garde As market watchers wonder whether Gilead Sciences is on the verge of a blockbuster buyout, the Big Biotech inked a small deal that will beef up its efforts in the growing ...

MaxCyte buys into CAR-T with Johns Hopkins partnership

Damian Garde Maryland biotech MaxCyte is delving into the world of CAR-T treatments for cancer, teaming up with Johns Hopkins University on a preclinical program. FierceBiotech News

Celgene buys into Mesoblast’s stem cell pipeline in regenerative med pact

John Carroll Celgene has stepped up with a deal to buy a $ 45 million chunk of Mesoblast's stock at a premium price in exchange for a front row seat on the Australian biotech's ...

Novartis makes concerted push into Israeli biotech startup scene

Nick Paul Taylor Over the past year, Novartis has struck a pair of deals in Israel, snagging an option to buy Gamida Cell and a stake in BioLineRx. FierceBiotech News

Court’s decision on Namenda ‘hard switch’ could spill over into precedent

Tracy Staton Last week, a New York judge called a halt on Actavis' plan to pull Namenda off the market, throwing off its strategy for switching patients to a newer extended-release ...

Google Ventures splashes into life sciences with its $425M purse

Damian Garde Google Ventures is betting more and more on life sciences startups each year, and the well-funded financier tells The Wall Street Journal that's not going to change ...

Billionaire Soon-Shiong dives into immuno-oncology with $20M Sorrento venture

Damian Garde Patrick Soon-Shiong, billionaire physician and biotech entrepreneur, wants in on the hottest field in oncology, forming a joint venture with Sorrento Therapeutics to develop ...

Bayer runs into another German roadblock in marketing vision drug Eylea

Tracy Staton Germany's cost-effectiveness watchdog said Bayer eye drug Eylea doesn't perform any better than its Novartis rival, Lucentis, as a treatment for diabetic macular ...

Report: Woodford is diving full on into biotech with new $314M fund

Damian Garde High profile U.K. investor Neil Woodford made headlines last week when he invested $ 25 million into Northwest Biotherapeutics, and that's a sign of much more to come, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS